Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Andrews

Showing results (91-100 of 101) with videos related to

Pageof 11
Sort By:
Bioorganic & Medicinal Chemistry|December 18, 2021
Identification and optimization of a novel series of selective PIP5K inhibitorsDavid M Andrews, Sharon Cartic, Sabina Cosulich, et al.
Chemical Communications (Cambridge, England)|December 25, 2013
Potent, selective small molecule inhibitors of type III phosphatidylinositol-4-kinase α- but not β-inhibit the phosphatidylinositol signaling cascade and cancer cell proliferationMichael J Waring, David M Andrews, Paul F Faulder, et al.
Viruses|March 30, 2023
Combined Use of RT-qPCR and NGS for Identification and Surveillance of SARS-CoV-2 Variants of Concern in Residual Clinical Laboratory Samples in Miami-Dade County, FloridaYamina L Carattini, Anthony Griswold, Sion Williams, et al.
ACS Chemical Biology|November 14, 2017
Identification and Characterization of Dual Inhibitors of the USP25/28 Deubiquitinating Enzyme SubfamilyJonathan D Wrigley, Gerald Gavory, Iain Simpson, et al.
Bioorganic & Medicinal Chemistry Letters|November 11, 2008
The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosingClifford D Jones, David M Andrews, Andrew J Barker, et al.
Plos One|August 3, 2017
Progress towards a public chemogenomic set for protein kinases and a call for contributionsDavid H Drewry, Carrow I Wells, David M Andrews, et al.
Bioorganic & Medicinal Chemistry Letters|September 26, 2008
Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitorsMalcolm Anderson, David M Andrews, Andy J Barker, et al.
Journal of Medicinal Chemistry|February 3, 2007
Optimization of novel acyl pyrrolidine inhibitors of hepatitis C virus RNA-dependent RNA polymerase leading to a development candidateMartin J Slater, Elizabeth M Amphlett, David M Andrews, et al.
Journal of Medicinal Chemistry|September 26, 2015
Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and AntagonistChris De Savi, Robert H Bradbury, Alfred A Rabow, et al.
International Journal of Molecular Sciences|January 12, 2021
The Kinase Chemogenomic Set (KCGS): An Open Science Resource for Kinase Vulnerability IdentificationCarrow I Wells, Hassan Al-Ali, David M Andrews, et al.
Pageof 11

Showing results (91-100 of 101) with videos related to

Sort By:
Pageof 11
Bioorganic & Medicinal Chemistry|December 18, 2021
Identification and optimization of a novel series of selective PIP5K inhibitorsDavid M Andrews, Sharon Cartic, Sabina Cosulich, et al.
Chemical Communications (Cambridge, England)|December 25, 2013
Potent, selective small molecule inhibitors of type III phosphatidylinositol-4-kinase α- but not β-inhibit the phosphatidylinositol signaling cascade and cancer cell proliferationMichael J Waring, David M Andrews, Paul F Faulder, et al.
Viruses|March 30, 2023
Combined Use of RT-qPCR and NGS for Identification and Surveillance of SARS-CoV-2 Variants of Concern in Residual Clinical Laboratory Samples in Miami-Dade County, FloridaYamina L Carattini, Anthony Griswold, Sion Williams, et al.
ACS Chemical Biology|November 14, 2017
Identification and Characterization of Dual Inhibitors of the USP25/28 Deubiquitinating Enzyme SubfamilyJonathan D Wrigley, Gerald Gavory, Iain Simpson, et al.
Bioorganic & Medicinal Chemistry Letters|November 11, 2008
The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosingClifford D Jones, David M Andrews, Andrew J Barker, et al.
Plos One|August 3, 2017
Progress towards a public chemogenomic set for protein kinases and a call for contributionsDavid H Drewry, Carrow I Wells, David M Andrews, et al.
Bioorganic & Medicinal Chemistry Letters|September 26, 2008
Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitorsMalcolm Anderson, David M Andrews, Andy J Barker, et al.
Journal of Medicinal Chemistry|February 3, 2007
Optimization of novel acyl pyrrolidine inhibitors of hepatitis C virus RNA-dependent RNA polymerase leading to a development candidateMartin J Slater, Elizabeth M Amphlett, David M Andrews, et al.
Journal of Medicinal Chemistry|September 26, 2015
Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and AntagonistChris De Savi, Robert H Bradbury, Alfred A Rabow, et al.
International Journal of Molecular Sciences|January 12, 2021
The Kinase Chemogenomic Set (KCGS): An Open Science Resource for Kinase Vulnerability IdentificationCarrow I Wells, Hassan Al-Ali, David M Andrews, et al.
Pageof 11